Jasper is excited to host a key opinion leader webinar on the potential of briquilimab in chronic urticaria. The event will begin at 8:00am EST tomorrow, 10/11. Link to register: lifescievents.com/event/jasper/
Latest posts 5
Jasper Therapeutics is pleased to announce that the FDA has accepted our IND application for briquilimab in #ChronicSpontaneousUrticaria. We look forward to initiating our phase 1b/2a study in CSU later this year. Read the full announcement: ir.jaspertherapeutics.com/news-releases/…
Jasper is excited to announce the addition of Patricia Carlos (SVP, Regulatory Affairs and Quality) and Annette Marcantonio (VP, Clinical Operations) to the team! ir.jaspertherapeutics.com/news-releases/…
Today we announced the first patient dosed in a Phase 1 trial, which is evaluating briquilimab’s therapeutic potential in targeting c-Kit for people with low-risk myelodysplastic syndrome. Read more: bit.ly/3qVeuYj #MDS
Today, we announced the appointment of Dr. Scott Brun to our Board of Directors. His 20+ years of drug development experience makes him an excellent asset as we advance briquilimab in chronic mast cell and stem cell-driven disease. Full announcement: ir.jaspertherapeutics.com/news-releases/…